Regulation - Pricing

Filter

Current filters:

Pricing

Popular Filters

101 to 125 of 326 results

Support for the Australia's PBS from Coalition Senators

22-08-2013

Ahead of the September 7 elections, Australian Coalition Senators have issued a statement acknowledging…

Asia-PacificPharmaceuticalPoliticsPricingRegulation

New Zealand proposals for influenza vaccines

21-08-2013

New Zealand's Pharmaceutical Management Agency PHARMAC is seeking feedback on a proposal to list two…

Abbott LaboratoriesAsia-PacificFluarixGlaxoSmithKlineInfluvacPharmaceuticalPricingRegulationVaccines

Japan's MHLW approves 367 generics, but what does this mean?

21-08-2013

Japan's Ministry of Health Labor and Welfare (MHLW) approved 367 items of generic drugs last week. Launch…

Asia-PacificDiovanGenericsNovartisPharmaceuticalPricingRegulation

NICE says Xalkori is not cost effective in ALK-positive NSCLC

20-08-2013

US pharma behemoth Pfizer (NYSE: PFE) has today (August 16) expressed concern and disappointment that…

EuropeOncologyPfizerPharmaceuticalPricingRegulationXalkori

IQWiG finds no added benefit proven for Constella in IBS

07-08-2013

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

AlmirallConstellaEuropeGastro-intestinalsIronwood PharmaceuticalsPharmaceuticalPricingRegulation

UK NICE guidance says breast cancer drug Perjeta not value for money

06-08-2013

The UK's National Health Service (NHS) is to be advised that it should not routinely provide Swiss drug…

BiotechnologyEuropeOncologyPerjetaPharmaceuticalPricingRegulationRoche

Germany's IQWiG confirms Jetrea's added value for VMT patients

02-08-2013

Belgian biopharma company ThromboGenics (Euronext Brussels: THR) announced today (August 2) that the…

BiotechnologyEuropeJetreaOphthalmicsPharmaceuticalPricingRegulationThromboGenics

UK's NICE calls for more data to consider Roche drug for a type of vasculitis

23-07-2013

UK drug watchdog the National Institute for Health and Care Excellence (NICE) has today (July 23) published…

BiotechnologyEuropeMabTheraOncologyPharmaceuticalPricingRare diseasesRegulationRoche

UK's NICE recommends hepatitis C treatment for children

18-07-2013

In draft guidance published this week, the UK's drugs watchdog the National Institute for Health and…

Anti-viralsBiotechnologyEuropeMerck & CoPegasysPharmaceuticalPricingRegulationRocheViraferonPeg

Negative NICE news for Pfizer leukemia drug

16-07-2013

There was disappointment for global drugs behemoth Pfizer (NYSE: OFE) when the UK drugs watchdog the…

BosulifEuropeOncologyPfizerPharmaceuticalPricingRegulation

IQWiG finds added benefit for Dificlir in C. difficile infections

16-07-2013

Germany's Institute for Quality and Efficiency in Health Care (IQWiG) has now assessed additional information…

Antibiotics and Infectious diseasesAstellas PharmaDificlirEuropePharmaceuticalPricingRegulation

First IQWiG assessment of the established drug market finds advantage for Januvia

15-07-2013

There are hints of a minor added benefit of US drug giant Merck & Co's (NYSE: MRK) Januvia (sitagliptin)…

DiabetesEuropeMerck & CoPharmaceuticalPricingRegulation

Celgene gets negative NICE view on Revlimid in rare blood cancer; presents new data in newly-diagnosed MM

11-07-2013

US biotech firm Celgene (Nasdaq: CELG) today (July 11) expressed disappointment at the preliminary decision…

BiotechnologyCelgeneEuropeOncologyPricingRare diseasesRegulationResearchRevlimid

Added benefit of Mitsubishi Tanabe's colestilan not proven, says German IQWiG

10-07-2013

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products (AMNOG),…

BindRencolestilanEuropeMitsubishi TanabeNephrology and HepatologyPharmaceuticalPricingRegulation

Ireland's HSE to reimburse InterMune's Esbriet for IPF

08-07-2013

US biotech firm InterMune's (Nasdaq: ITMN) UK subsidiary says that Ireland's Health Service Executive…

BiotechnologyEsbrietEuropeInterMunePricingRegulationRespiratory and Pulmonary

Proposal for a sole supply arrangement for fentanyl patches in New Zealand

08-07-2013

New Zealand's Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal to list a…

Asia-PacificfentanylFentanyl SandozNeurologicalNovartisPharmaceuticalPricingRegulationSandoz

Novartis breast cancer drug Afinitor not cost effective for NHS, says draft NICE guidance

08-07-2013

Swiss drug major Novartis' (NOVN: VX) breast cancer drug Afinitor (everolimus) is not recommended as…

AfinitorEuropeNovartisOncologyPharmaceuticalPricingRegulation

Largely negative views from Germany's IQWiG on AstraZeneca's Caprelsa in thyroid cancer

26-06-2013

In a new benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG) has…

AstraZenecaCaprelsaEuropeOncologyPharmaceuticalPricingRegulation

Setback for myelofibrosis patients as UK's NICE rejects Novartis' Jakavi

26-06-2013

Swiss drug major Novartis today (June 26) expressed disappointment at the decision of UK drugs watch…

EuropeJakaviNovartisOncologyPharmaceuticalPricingRegulation

Eisai temporarily suspend Fycompa in Germany, following negative G-BA decision

25-06-2013

Japanese drug major Eisai (TYO: 4523) said today (June 25) that, "with regret," it will suspend temporarily…

EisaiEuropeFycompaMarkets & MarketingNeurologicalPharmaceuticalPricingRegulation

A$5 billion worth of drugs have gained PBS listing in Australia since 2007

24-06-2013

The Labour government in Australia has approved the listing of over A$5 billion ($4.6 billion) worth…

Asia-PacificPharmaceuticalPricingRegulation

UK's NICE issues negative new draft guidance on Sanofi's Zaltrap

21-06-2013

The UK's drug watchdog the National Institute for Health Care and Excellence (NICE) has issued new draft…

EuropeOncologyPharmaceuticalPricingRegulationSanofiZaltrap

101 to 125 of 326 results

Back to top